ABIGAIL GREGORY: Open Payments
NPI 1063880714 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,112 in 117 payments from 16 companies in 2025. Trend: 2023 $1,579 · 2024 $1,671 · 2025 $2,112
Food & beverage: $2,027Education: $85
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 16 | $436 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 16 | $307 |
| ABBVIE INC. | 27 | $304 |
| Janssen Biotech, Inc. | 13 | $269 |
| Lilly USA, LLC | 10 | $160 |
| Novartis Pharmaceuticals Corporation | 13 | $156 |
| Regeneron Healthcare Solutions, Inc. | 5 | $122 |
| PFIZER INC. | 4 | $59 |
| E.R. Squibb & Sons, L.L.C. | 3 | $58 |
| Amgen Inc. | 3 | $53 |
Products named: Bimzelx, TREMFYA, RINVOQ, DUPIXENT, SKYRIZI, TALTZ, Winlevi, ILUMYA.
Industry payments across IN — which companies pay providers there.
